News | January 04, 2007

Docs, Investors Await News on Plaque Drug

Jan. 5, 2007 — An announcement from AstraZeneca is expected soon about the company’s experimental heart drug AGI-1067, the company’s partner AtheroGenics Inc. hopes to present results from a pivotal Phase III clinical trial to the American College of Cardiology (ACC) meeting in New Orleans. Deadline for research submissions was yesterday, and therefore, analysts surmise, AtheroGenics may be negotiating with ACC what news it and AstraZeneca can release to investors prior to the meeting.

An AstraZeneca spokesman said the news was still expected early in 2007. Meanwhile Atherogenics CEO Russell Medford is slated to address J.P. Morgan's annual healthcare conference Jan. 10.

In December of 2005 AstraZeneca agreed to pay AtheroGenics up to $1 billion for exclusive rights to AGI-1067, an anti-inflammatory product designed to reduce the build-up of plaque inside arteries that can lead to heart attack and stroke.

AGI-1067 belongs to a small group of experimental medicines aimed at treating atherosclerosis. If successful, it and rival products from GlaxoSmithKline and Iceland's Decode Genetics Inc. could be the next major advance in treating heart disease — current treatments for atherosclerosis are anti-inflammatory drugs, which reduce the risk of disease progressing by only 30 to 35 percent.

In December, Pfizer Inc.’s key new medicine torcetrapib, did not prove to be successful in raising levels of "good" HDL cholesterol.

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init